Summary:
This research study will be used to evaluate the long term safety of a specific MS treatments or another disease modifying therapy in patients with MS newly started with the study medication.
To join in the Study, you must have a relapsing form of MS. This Study is for patients who will be starting a specific study medication at the start of the study or are starting another DM or started within 6 month of the study entry. Patients previously or currently treated with cytotoxic agents or natalizumab cannot participate in this study. Must be 18 years or older.
Qualified Participants May Receive:
Pulmonary Functional Test by the study, A Dermatology visit by the study and a 50 dollars compensation for each visit.